Literature DB >> 12767177

Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors.

David T Puerta1, Seth M Cohen.   

Abstract

The tetrahedral zinc complex [(Tp(Ph,Me))ZnOH] (Tp(Ph,Me) = hydrotris(3,5-phenylmethylpyrazolyl)borate) was combined with 1-hydroxy-2(1H)-pyridinone, 3-hydroxy-2(1H)-pyridinone, 3-hydroxy-1-methyl-2(1H)-pyridinone, 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone, 1-hydroxy-2(1H)-pyridinethione, and 3-hydroxy-2-methyl-4-pyrone to generate the complexes [(Tp(Ph,Me))Zn(ZBG)] (ZBG = zinc-binding group). These complexes were synthesized to explore the coordination geometry of potential novel zinc-binding groups for use in matrix metalloproteinase (MMP) inhibitors. The solid-state structures of all six metal complexes were determined by X-ray crystallography. These structures combined with IR and (1)H NMR data demonstrate that these ZBGs bind in a strong, bidentate fashion to the zinc(II) ion. Modeling studies indicate that these ZBGs can easily fit into the MMP active site. In an effort to develop more effective inhibitors of MMPs, this work has revealed molecular-level interactions for six potential new ZBGs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767177     DOI: 10.1021/ic026029g

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  30 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

2.  Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

Authors:  Jennifer A Jacobsen; Jessica L Fullagar; Melissa T Miller; Seth M Cohen
Journal:  J Med Chem       Date:  2010-12-28       Impact factor: 7.446

3.  Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity.

Authors:  David T Puerta; Michael O Griffin; Jana A Lewis; Diego Romero-Perez; Ricardo Garcia; Francisco J Villarreal; Seth M Cohen
Journal:  J Biol Inorg Chem       Date:  2005-12-03       Impact factor: 3.358

Review 4.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

5.  Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site.

Authors:  David P Martin; Zachary S Hann; Seth M Cohen
Journal:  Inorg Chem       Date:  2013-05-24       Impact factor: 5.165

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

7.  Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.

Authors:  Irene de Miguel; Josune Orbe; Juan A Sánchez-Arias; José A Rodríguez; Agustina Salicio; Obdulia Rabal; Miriam Belzunce; Elena Sáez; Musheng Xu; Wei Wu; Haizhong Tan; Hongyu Ma; José A Páramo; Julen Oyarzabal
Journal:  ACS Med Chem Lett       Date:  2018-04-16       Impact factor: 4.345

8.  Bidentate Zinc chelators for alpha-carbonic anhydrases that produce a trigonal bipyramidal coordination geometry.

Authors:  Johannes Schulze Wischeler; Alessio Innocenti; Daniela Vullo; Arpita Agrawal; Seth M Cohen; Andreas Heine; Claudiu T Supuran; Gerhard Klebe
Journal:  ChemMedChem       Date:  2010-09-03       Impact factor: 3.466

Review 9.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

10.  Identification of new snake venom metalloproteinase inhibitors using compound screening and rational Peptide design.

Authors:  Fabián Villalta-Romero; Anna Gortat; Andrés E Herrera; Rebeca Arguedas; Javier Quesada; Robson Lopes de Melo; Juan J Calvete; Mavis Montero; Renato Murillo; Alexandra Rucavado; José María Gutiérrez; Enrique Pérez-Payá
Journal:  ACS Med Chem Lett       Date:  2012-06-14       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.